Evidence map›Paper›PMID 23817979›Full record

ArticleArthritis and rheumatism2013

Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease.

Van C Willis, M Kristen Demoruelle, Lezlie A Derber, Catherine J Chartier-Logan, Mark C Parish, Isabel F Pedraza, Michael H Weisman, Jill M Norris, V Michael Holers, Kevin D Deane

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Arthritis and rheumatism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04474392 (Sputum Studies of Anti-Citrullinated Protein Antibodies), which is not on this map. Cited by 130 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 2 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04474392 completednot on this mapstarted 2020, after this paper: background citation

Sputum Studies of Anti-Citrullinated Protein Antibodies (ACPA) and Rheumatoid Arthritis (RA) Origins

TypeobservationalSponsorUniversity of Colorado, DenverRan2020 to 2026Enrolled340ConditionsRheumatoid ArthritisArmsN/A (Observational Study)
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 2 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Lung disease in rheumatoid arthritis.Nature reviews. Rheumatology · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Induced sputum: current progress and prospect.European journal of medical research · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Van C WillisUniversity of Colorado, Aurora.
M Kristen Demoruelle
Lezlie A Derber
Catherine J Chartier-Logan
Mark C Parish
Isabel F Pedraza
Michael H Weisman
Jill M Norris
V Michael Holers
Kevin D Deane
Cedars-Sinai Medical Center · USColorado School of Public Health · US

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Virginia Mason/UCHSC Autoimmune Prevention CenterU19AI050864 · NIAID · UNIVERSITY OF COLORADO DENVER · PI EISENBARTH, GEORGE S · 2001 to 2011
$29.2M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Prevention Center U01: Early Targets for Antigen-Specific Tolerance Induction in Preclinical Rheumatoid ArthritisU01AI101981 · NIAID · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2012 to 2021
$6.2M
RA-Related Autoantibodies in Healthy FDR of RA PatientsR01AR051394 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI NORRIS, JILL M · 2005 to 2011
$3.0M
Colorado Clinical and Translational Sciences InstituteTL1TR001081 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$1.3M
Colorado Clinical and Translational Science Institute (TL1)TL1RR025778 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$730k
Colorado Clinical and Translational Science Institute (TL1)TL1TR000155 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$294k
NCATS NIH HHS TL1 TR000155NCATS NIH HHS TL1-TR-000155NCATS NIH HHS TL1 TR001081NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1-TR-000154NCATS NIH HHS UL1 TR001082NCRR NIH HHS TL1 RR025778NIAID NIH HHS U01 AI101981NIAID NIH HHS U01-AI-101981NIAID NIH HHS U19 AI050864NIAID NIH HHS U19-AI-050864NIAMS NIH HHS R01 AR051394NIAMS NIH HHS R01-AR-051395
6 · The paper itself

Abstract

objectiveTo evaluate the generation of rheumatoid arthritis (RA)-related autoantibodies in the lung.

methodsSimultaneous collection of serum and induced sputum was performed in 21 healthy controls, 49 at-risk subjects without inflammatory arthritis but at risk of RA due to family history or seropositivity for anti-citrullinated protein antibodies, and 14 subjects with early RA. Samples were tested for anti-cyclic citrullinated peptide 2 (anti-CCP2), anti-CCP3, anti-CCP3.1, rheumatoid factor isotypes IgM, IgG, and IgA, and total IgM, IgG, and IgA.

resultsOne or more autoantibodies were present in sputum of 39% of at-risk seronegative subjects, 65% of at-risk seropositive subjects, and 86% of subjects with early RA. In at-risk seronegative subjects, the rate of anti-CCP3.1 positivity and the median number of autoantibodies were elevated in sputum versus serum. In subjects with early RA, the rate of positivity for several individual autoantibodies and the median number of autoantibodies were higher in serum than in sputum. Results in at-risk seropositive subjects were intermediate between these groups. In at-risk subjects with autoantibody positivity in sputum, the ratios of autoantibody to total Ig were higher in sputum than in serum, suggesting that these autoantibodies are generated or sequestered in the lung.

conclusionRA-related autoantibodies are detectable in sputum in subjects at risk of RA and in subjects with early RA. In a subset of at-risk subjects, the presence of sputum autoantibodies in the absence of seropositivity, and the increased autoantibody-to-total Ig ratios in sputum, suggest that the lung may be a site of autoantibody generation in the early development of RA. These findings suggest an important role of the lung in the pathogenesis of RA.

Indexed as

Disease ProgressionAdultAgedArthritis, RheumatoidAutoantibodiesCase-Control StudiesFemaleHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MLungMaleMiddle AgedPeptides, CyclicRheumatoid FactorAutoantibodiescyclic citrullinated peptideImmunoglobulin AImmunoglobulin GImmunoglobulin MPeptides, CyclicRheumatoid Factor

Identifiers

PMID23817979
PMCPMC4066465
OpenAlexW1980379994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.